ArticleBlood2013

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Zijun Y Xu-Monette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.